{'fraction_non_alphanumeric': 0.01564945226917058, 'fraction_numerical': 0.017214397496087636, 'mean_word_length': 4.8136363636363635, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Editor takes a closer look at some of this month's articles

One of the most exciting and fast moving areas in the management of allergic disease is the resolution provided by measuring responsiveness to individual allergens rather than whole extracts; an approach often called molecular or component resolved diagnosis [1, 2]. An increasing number of papers are appearing which provide evidence that using this approach could make a significant difference to management, in particular by helping to predict the risk in sensitised individuals of severe reactions upon allergen exposure. In this issue, Alessandri et al. (pp. 441-450) contribute to this literature by showing that the egg allergen, Gal d 1 discriminates between reactivity and tolerance to egg. They challenged 68 children with suspected egg allergy with boiled and raw eggs and related the response to IgE sensitisation to individual egg allergens on a microarray. They found that 20 of 21 patients sensitised to Gal d 1 reacted to raw egg whereas 44 of 47 Gal d 1 negative patients could tolerate boiled egg. None of the other allergens had any discriminative power. It will be interesting to see the extent to which knowledge of Gal d 1 status will obviate the need for egg challenge in clinical practice.